Myriad initiated by Rodman & Renshaw at market outperform

Myriad Genetics Inc. coverage was initiated by Rodman & Renshaw analyst Matthew Murray at a market outperform rating with a price target on the stock of $29 per share. Myriad shares Friday were up $0.25, or 1.22%, at $20.82 on volume of 339,265 shares versus the three-month running average of 313,415 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.